menu
    • menu

    Company profile for Cleave Therapeutics

    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    With Virupaksha, you get a quality product with on-time delivery.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-11-24

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    ChemExpress delivers end-to-end CRO & CDMO solutions for small molecules, biologics & new modalities with ICH-grade quality.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Cleave Therapeutics is a clinical stage biopharmaceutical company focused on valosin-containing protein (VCP)/p97 as a novel target in protein homeostasis and cellular stress pathways for therapeutic use in cancer and neurodegenerative diseases. There is a growing body of evidence around inhibiting VCP to target cancer stress pathways with known biological relevance in cancer. Cleave has ongoing collaborations with the Nationa...
    Cleave Therapeutics is a clinical stage biopharmaceutical company focused on valosin-containing protein (VCP)/p97 as a novel target in protein homeostasis and cellular stress pathways for therapeutic use in cancer and neurodegenerative diseases. There is a growing body of evidence around inhibiting VCP to target cancer stress pathways with known biological relevance in cancer. Cleave has ongoing collaborations with the National Cancer Institute (NCI) and leading academic institutions, as well as strategic investment from Astellas and Bristol Myers Squibb.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Cleave TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    135 Main Street Suite 1145 San Francisco, CA 94105
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://cleavetherapeutics.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/cleavetherapeutics/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    DDL Conference

    Not Confirmed

    envelop Contact Supplier

    DDL Conference

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Cleave Therapeutics Announces Acquisition of Clinical and Preclinical Assets
    Cleave Therapeutics Announces Acquisition of Clinical and Preclinical Assets

    20 Jul 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20230720193642/en

    BUSINESSWIRE
    20 Jul 2023
    Share Share
    BioNTech inks cancer deal with Chinese biotech; Eikon, CASI buy Cleave’ assets
    BioNTech inks cancer deal with Chinese biotech; Eikon, CASI buy Cleave’ assets

    20 Jul 2023

    // Paul Schloesser ENDPTS

    https://endpts.com/biontech-inks-cancer-deal-with-chinese-biotech-eikon-casi-buy-cleave-therapeutics-assets/

    Paul Schloesser ENDPTS
    20 Jul 2023
    Share Share
    CASI AND CLEAVE THERAPEUTICS ANNOUNCE TRIAL APPLICATION APPROVAL FOR CB-5339
    CASI AND CLEAVE THERAPEUTICS ANNOUNCE TRIAL APPLICATION APPROVAL FOR CB-5339

    06 Jan 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/casi-pharmaceuticals-and-cleave-therapeutics-announce-clinical-trial-application-approval-for-cb-5339-in-patients-with-multiple-myeloma-in-china-301715199.html

    PR NEWSWIRE
    06 Jan 2023
    Share Share
    Cleave Licenses CB-5339 To CASI Pharmaceuticals For Greater China Region
    Cleave Licenses CB-5339 To CASI Pharmaceuticals For Greater China Region

    08 Mar 2021

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/cleave-therapeutics-licenses-first-in-class-vcpp97-inhibitor-cb-5339-to-casi-pharmaceuticals-for-greater-china-region-301242012.html

    PRNEWSWIRE
    08 Mar 2021
    Share Share

    ABOUT THIS PAGE

    Contact Cleave Therapeutics and get a quotation

    Cleave Therapeutics is a supplier offers 3 products (APIs, Excipients or Intermediates).

    Find a price of CB-5339 bulk with DMF offered by Cleave Therapeutics

    Find a price of CB-5083 CAPSULES bulk offered by Cleave Therapeutics

    Find a price of CB-5083 DRUG SUBSTANCE bulk offered by Cleave Therapeutics

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search